Lumida
/AVNS
⌘K
Avanos Medical Inc

Avanos Medical Inc

AVNS
$24.99USD+0.04%+0.01 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$25 – $25

52W RANGE

$9
$25

AI Summary

Stalk
StalkMedium

AVNS remains in a Stage 2 advancing trend with a bullish structural bias. A Devil’s Bargain continuation pattern suggests potential near-term upside extension, but current consolidation above flat EMAs and overbought RSI indicate a likely pause. Price is tightly tracking above the 9EMA and 20EMA, offering potential pullback entry zones. On balance, the medium-term bias is bullish, but execution should be deferred until a favorable pullback into support.

  • Specialty nutrition segment delivered 8% organic growth in 2025.
  • Nexus Medical integration adds ~$5M revenue targeting double-digit growth.
  • Tariffs impose ~$30M manufacturing costs in 2026, pressuring margins.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$587.0M$684.1M$673.3M$687.8M$701.2M
YoY %-17.9%+16.5%-1.6%+2.2%+1.9%
P / Sales2.9x1.9x1.6x1.1x0.7x
EV / Sales3.2x2.4x2.1x1.4x1.0x
Gross Profit, Adj.$299.2M$394.2M$379.7M$381.3M$353.9M
YoY %-19.3%+31.8%-3.7%+0.4%-7.2%
Margin %51.0%57.6%56.4%55.4%50.5%
EV / Gross Profit6.3x4.2x3.8x2.5x2.1x
EBITDA, Adj.$-700,000$83.2M$63.6M$82.1M$53.9M
YoY %+87.5%+11985.7%-23.6%+29.1%-34.3%
Margin %-0.1%12.2%9.4%11.9%7.7%
EV / EBITDA-2713.5x19.8x22.4x11.6x13.5x
EBIT$-39.0M$35.5M$17.5M$-400.1M$-62.0M
YoY %+19.6%+191.0%-50.7%-2386.3%+84.5%
Margin %-6.6%5.2%2.6%-58.2%-8.8%
EV / EBIT-48.7x46.5x81.4x-2.4x-11.7x
Net Income$6.3M$50.5M$-61.8M$-392.1M$-72.9M
YoY %+121.7%+701.6%-222.4%-534.5%+81.4%
Net Margin1.1%7.4%-9.2%-57.0%-10.4%
EPS (GAAP)$0.13$1.07-$1.32-$8.53-$1.57
YoY %+121.3%+723.1%-223.4%-546.2%+81.6%